BioCentury
ARTICLE | Clinical News

BL-8040: Phase I data

April 13, 2015 7:00 AM UTC

BioLineRx reported top-line data from a 2-part, Israeli Phase I trial in 32 healthy volunteers showing that subcutaneous BL-8040 met all safety and efficacy endpoints. BL-8040 was well tolerated at al...